Laurus Labs (LAURUS)’s Annual Report Analysis indicates a sharp improvement in
ROE, led by a strong head-start in Finished dosage forms (FDF), improving operating
profit, and a reduced interest rate, the brokerages have upgraded their target as well;
ROE, led by a strong head-start in Finished dosage forms (FDF), improving operating
profit, and a reduced interest rate, the brokerages have upgraded their target as well;
免责声明
这些信息和出版物并非旨在提供,也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供,也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
